Profile data is unavailable for this security.
About the company
AbCellera Biologics Inc. is focused on the development of antibody-based drugs and is committed to improving discovery and development. It is engaged in antibody discovery and development engine is specifically designed to break the barriers of conventional discovery. It provides biotech and pharmaceutical companies with an advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. The Company uses the engine to both work with partners to build a large and diversified portfolio of royalty stakes in antibody drugs and to develop its own pipeline of antibody drugs. The Company partners with companies of all sizes, from biotechnology companies to pharmaceutical companies-propelling programs to the clinic, together. It generates a range of diverse antibodies with immunization strategies and single-cell screening.
- Revenue in USD (TTM)38.03m
- Net income in USD-146.40m
- Incorporated2012
- Employees586.00
- LocationAbcellera Biologics Inc2215 Yukon StreetVANCOUVER V5Y 0A1CanadaCAN
- Phone+1 (604) 559-9005
- Websitehttps://www.abcellera.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vir Biotechnology Inc | 86.18m | -615.06m | 1.09bn | 587.00 | -- | 0.6814 | -- | 12.60 | -4.59 | -4.59 | 0.6425 | 11.80 | 0.0365 | -- | -- | 146,814.30 | -26.06 | -0.6081 | -30.49 | -0.7192 | 96.79 | -- | -713.76 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
| Scholar Rock Holding Corp | 0.00 | -165.79m | 1.10bn | 150.00 | -- | 4.75 | -- | -- | -1.99 | -1.99 | 0.00 | 2.96 | 0.00 | -- | -- | 0.00 | -49.55 | -38.14 | -55.26 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.1817 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
| Prothena Corporation PLC | 91.37m | -147.03m | 1.10bn | 173.00 | -- | 1.97 | -- | 12.09 | -2.80 | -2.80 | 1.68 | 10.46 | 0.1256 | -- | -- | 528,150.30 | -20.22 | -14.20 | -21.82 | -15.11 | -- | -- | -160.92 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
| Belite Bio Inc (ADR) | 0.00 | -31.63m | 1.11bn | 20.00 | -- | 12.01 | -- | -- | -1.24 | -1.24 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -45.54 | -- | -47.50 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
| Mirum Pharmaceuticals Inc | 186.37m | -163.42m | 1.13bn | 264.00 | -- | 4.51 | -- | 6.06 | -4.08 | -4.08 | 4.56 | 5.32 | 0.3729 | 3.37 | 4.05 | 705,962.10 | -32.70 | -38.93 | -38.55 | -44.88 | 74.76 | -- | -87.68 | -190.71 | 4.19 | -79.67 | 0.552 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
| MannKind Corp | 198.96m | -11.94m | 1.13bn | 414.00 | -- | -- | -- | 5.70 | -0.0464 | -0.0464 | 0.7087 | -0.9116 | 0.5165 | 2.50 | 12.55 | 480,584.50 | -3.10 | -26.07 | -3.99 | -37.80 | 68.45 | 59.68 | -6.00 | -57.61 | 3.31 | 0.5023 | 1.90 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
| AbCellera Biologics Inc | 38.03m | -146.40m | 1.14bn | 586.00 | -- | 0.9843 | -- | 30.03 | -0.5062 | -0.5062 | 0.1315 | 3.96 | 0.0251 | -- | 1.10 | 64,890.79 | -9.67 | 6.08 | -10.49 | 6.67 | -- | -- | -384.99 | 24.69 | 7.32 | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
| Pharvaris NV | 0.00 | -107.91m | 1.14bn | 82.00 | -- | 2.70 | -- | -- | -2.70 | -2.70 | 0.00 | 7.86 | 0.00 | -- | -- | 0.00 | -35.62 | -36.09 | -37.81 | -38.27 | -- | -- | -- | -- | -- | -33.51 | 0.0006 | -- | -- | -- | -32.15 | -- | -- | -- |
| Collegium Pharmaceutical Inc | 566.77m | 48.16m | 1.16bn | 197.00 | 40.22 | 5.79 | 5.88 | 2.05 | 0.8823 | 0.8823 | 12.53 | 6.13 | 0.4891 | 6.10 | 3.13 | 2,876,990.00 | 4.16 | 2.79 | 6.75 | 4.80 | 57.55 | 50.88 | 8.50 | 5.16 | 1.10 | 2.59 | 0.7734 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
| Xencor Inc | 168.34m | -126.09m | 1.16bn | 280.00 | -- | 1.73 | -- | 6.91 | -2.10 | -2.10 | 2.79 | 10.96 | 0.1872 | -- | 8.36 | 601,207.10 | -14.04 | -3.70 | -15.30 | -4.12 | -- | -- | -75.00 | -15.92 | -- | -- | 0.0304 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
| Deciphera Pharmaceuticals Inc | 163.36m | -194.94m | 1.18bn | 355.00 | -- | 3.35 | -- | 7.23 | -2.29 | -2.29 | 1.92 | 4.36 | 0.3522 | 0.1787 | 6.01 | 460,157.80 | -42.03 | -44.54 | -52.63 | -52.24 | 97.72 | -- | -119.34 | -245.88 | 3.59 | -- | 0.00 | -- | 21.87 | -- | -8.95 | -- | -7.11 | -- |
| Pacira Biosciences Inc | 674.98m | 41.96m | 1.20bn | 711.00 | 38.15 | 1.38 | 10.24 | 1.78 | 0.6789 | 0.6789 | 12.33 | 18.72 | 0.4147 | 1.84 | 6.62 | 949,336.10 | 2.58 | 3.35 | 2.79 | 3.98 | 72.64 | 72.63 | 6.22 | 8.57 | 4.17 | 9.85 | 0.3752 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
| Spyre Therapeutics Inc | 886.00k | -338.79m | 1.21bn | 30.00 | -- | -- | -- | 1,362.78 | -75.04 | -75.04 | 0.1285 | 7.45 | 0.0043 | -- | 4.73 | 29,533.33 | -164.06 | -101.87 | -184.94 | -118.83 | -- | -- | -38,238.15 | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
| Tarsus Pharmaceuticals Inc | 17.45m | -135.89m | 1.23bn | 244.00 | -- | 5.69 | -- | 70.40 | -4.58 | -4.58 | 0.5939 | 5.76 | 0.0707 | -- | 1.64 | 71,504.10 | -55.09 | -31.56 | -61.63 | -33.82 | 90.87 | -- | -778.89 | -242.59 | 6.85 | -- | 0.1315 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
Data as of Apr 25 2024. Currency figures normalised to Abcellera Biologics Inc's reporting currency: US Dollar USD
29.30%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baillie Gifford & Co.as of 31 Dec 2023 | 24.04m | 8.21% |
| Baker Bros. Advisors LPas of 31 Dec 2023 | 22.91m | 7.83% |
| Voya Investment Management Co. LLCas of 31 Dec 2023 | 10.62m | 3.63% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2023 | 8.35m | 2.85% |
| Credit Suisse Asset Management (Schweiz) AGas of 31 Dec 2023 | 4.57m | 1.56% |
| ArrowMark Colorado Holdings LLCas of 31 Dec 2023 | 4.11m | 1.40% |
| Lazard Asset Management LLCas of 31 Dec 2023 | 3.41m | 1.17% |
| Hermes Investment Management Ltd.as of 31 Dec 2023 | 3.02m | 1.03% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 2.39m | 0.82% |
| Casdin Capital LLCas of 31 Dec 2023 | 2.36m | 0.81% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
